This article is produced by the TotalCareMedical.com editorial team for informational and educational purposes only. It does not constitute medical advice. The clinical information presented here applies to GLP-1 and GLP-1/GIP receptor agonist medications generally and to compounded versions specifically where noted. Always consult a licensed healthcare provider regarding side effects, contraindications, and medical decisions specific to your health profile. Compounded medications are not FDA-approved.
Why Side Effect Literacy Matters Before Starting GLP-1 Therapy
GLP-1 receptor agonist medications — and the newer GLP-1/GIP dual agonists like tirzepatide — produce meaningful clinical effects by altering the hormonal signaling involved in appetite regulation, gastric motility, and blood sugar management. Those same mechanisms produce the majority of the side effects patients experience. Understanding what to expect, when side effects are normal and transient versus when they signal a problem, and what compounded medication adds to the risk picture is foundational to informed decision-making before starting any program in this category.
Gala GLP-1's platform facilitates access to compounded GLP-1/GIP medication. For a full review of the platform and its structure, see: Gala GLP-1 Review 2026. For an explanation of the mechanism behind GLP-1 and GIP receptor agonism, see: How Gala GLP-1 Works. This article focuses on the safety and side effect dimension that the editorial team treats as a trust-building obligation — not an afterthought.
Most Common Side Effects: Gastrointestinal
The most commonly reported side effects of GLP-1 receptor agonist therapy are gastrointestinal. This is a direct consequence of the mechanism: GLP-1 slows gastric emptying — food moves through the stomach and intestines more slowly. The clinical literature on semaglutide and tirzepatide consistently identifies nausea, constipation, diarrhea, vomiting, and abdominal discomfort as the leading adverse effects, particularly during dose initiation and escalation. In the SURMOUNT-1 trial of brand-name tirzepatide — conducted under controlled clinical conditions with the FDA-approved product — nausea and diarrhea were among the most frequently reported adverse effects, most commonly occurring during dose escalation, according to data published in the New England Journal of Medicine in 2022. This data reflects the brand-name product in a clinical trial setting and is provided as context for the therapeutic class; it does not directly characterize compounded tirzepatide.
Gradual dose titration is the standard clinical approach to managing gastrointestinal side effects. Starting at a lower dose and increasing incrementally over weeks gives the body time to adjust to the altered gastric motility. This is why Gala GLP-1's stated protocol — and the protocols of responsible GLP-1 telehealth platforms generally — start patients at a lower dose regardless of prior experience with GLP-1 therapy. The editorial team notes that at least one third-party reviewer reported frustration when Gala's initial prescription reflected a starting dose lower than expected based on prior GLP-1 experience. That frustration is understandable, but standard-of-care titration is a clinical safety decision, not an error. Patients who have established GLP-1 tolerance should communicate their prior dosing history clearly during the intake assessment.
Practical management strategies for gastrointestinal side effects that are consistent with clinical guidance include: eating smaller meals and avoiding high-fat or high-sugar meals on injection days; staying adequately hydrated; avoiding lying down immediately after eating; and using the platform's asynchronous messaging to communicate with a provider about side effect severity rather than self-adjusting dose timing or amount.
Less Common but Clinically Significant Side Effects
Beyond the common gastrointestinal effects, the clinical literature and FDA safety communications identify several less common but more serious adverse events associated with GLP-1 receptor agonist therapy that patients should be aware of before starting.
Pancreatitis: Cases of acute pancreatitis have been reported with GLP-1 medications. Severe, persistent abdominal pain — particularly pain that radiates to the back — warrants immediate contact with a healthcare provider or emergency care. Patients with a history of pancreatitis should disclose this during the clinical intake; it is a contraindication consideration for GLP-1 therapy.
Thyroid concerns: In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors. The FDA includes a boxed warning on brand-name GLP-1 medications regarding the risk of thyroid tumors, specifically medullary thyroid carcinoma. Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) should not use GLP-1 receptor agonist medications. This contraindication is assessed during provider review and should be disclosed fully in the clinical intake.
Gallbladder effects: Rapid weight loss can increase the risk of gallstone formation. GLP-1 therapy-associated gallbladder events, including cholelithiasis and cholecystitis, have been reported in clinical trial populations. Patients with a history of gallbladder disease should discuss this with their provider.
Heart rate changes: GLP-1 receptor agonists have been associated with increased heart rate in some patients. This is generally modest in clinical studies but warrants monitoring, particularly in patients with underlying cardiac conditions.
Hypoglycemia: For patients without type 2 diabetes using GLP-1 medications for weight management, the risk of hypoglycemia is low on its own. The risk increases when GLP-1 therapy is combined with other glucose-lowering medications, including sulfonylureas or insulin. Patients on multiple medications affecting blood glucose should discuss the combined risk with a licensed provider.
Compounded Medication Safety: Additional Considerations
The side effects described above are associated with the GLP-1 receptor agonist therapeutic class based on clinical data from FDA-approved medications. Compounded GLP-1 medications — including those available through Gala GLP-1 — introduce an additional safety dimension that is distinct from therapeutic class effects.
The FDA has received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports linked to compounded tirzepatide as of early 2025, with many involving dosing errors — specifically, patients self-administering incorrect doses from multidose vials. Some of these errors resulted in hospitalization. The editorial team cites this data not to characterize Gala GLP-1's specific pharmacy network, which was not individually audited, but because the pattern applies to any compounded GLP-1 program: the multidose vial format common in compounding creates a dose-calculation step that pre-filled brand-name auto-injectors do not require. Patients using compounded injectables should read all dosing instructions carefully, confirm their dose calculation with their provider, and contact the platform's messaging system immediately if any uncertainty exists about the correct dose before administration.
Quality across compounding pharmacies is not uniform. The FDA does not approve compounded finished products. 503A pharmacies operate under state pharmacy board oversight and must comply with USP 797 sterile compounding standards. 503B outsourcing facilities face stricter federal oversight requirements. Gala GLP-1's public materials do not specify whether partner pharmacies operate as 503A or 503B facilities. Prospective patients should ask the platform directly which type of pharmacy will fill their prescription and whether that pharmacy is currently operating in compliance with applicable regulations in the current enforcement environment.
For patients who have questions about compounded GLP-1 sourcing and pharmacy standards, the editorial team has reviewed Direct Meds GLP-1 Compound, which provides additional context on how compounding pharmacy sourcing works across this telehealth category.
When to Contact Your Provider or Seek Emergency Care
Contact your Gala GLP-1 provider through the platform's messaging system for: persistent or worsening nausea that is significantly affecting food intake or hydration; constipation lasting more than a week despite hydration and dietary adjustment; unexpected changes in heart rate; questions about your dose or how to administer it; any side effect that concerns you, regardless of severity.
Seek emergency medical care immediately for: severe or persistent abdominal pain (possible pancreatitis or gallbladder event); signs of severe allergic reaction including hives, difficulty breathing, or swelling of the face, lips, tongue, or throat; fainting or severe dizziness; vision changes; or any symptom that feels acute, unusual, or alarming.
Do not self-adjust your dose without contacting a licensed provider first. If you are experiencing a side effect that makes your current dose difficult to tolerate, the platform's asynchronous messaging exists specifically to address this — use it.
Frequently Asked Questions
What are the most common side effects of GLP-1 therapy?
The most commonly reported side effects are gastrointestinal: nausea, constipation, diarrhea, vomiting, and abdominal discomfort. These effects are most pronounced during dose initiation and escalation and typically diminish as the body adjusts. Gradual dose titration is the standard clinical approach to managing these effects.
Are the side effects of compounded tirzepatide different from brand-name Zepbound?
The active ingredient in compounded tirzepatide is the same as in brand-name Zepbound and Mounjaro. However, compounded medications are not FDA-approved and have not undergone the same standardized manufacturing review. The FDA has received adverse event reports linked to compounded GLP-1 medications, including dosing errors from multidose vials. Quality varies by compounding pharmacy. Patients should confirm that their pharmacy has current USP 797 sterile compounding certification and third-party purity testing.
Who should not use GLP-1 medications?
Individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use GLP-1 receptor agonists. Other contraindications include a history of pancreatitis, severe gastrointestinal motility disorders, and certain other conditions. A licensed healthcare provider evaluates contraindications during the clinical intake process.
What should I do if I experience severe side effects?
Contact your prescribing healthcare provider immediately for persistent or severe side effects. Seek emergency medical care for symptoms of severe allergic reaction, severe abdominal pain that may indicate pancreatitis, vision changes, or other acute symptoms. Do not self-adjust your dose without consulting a licensed provider first.